Patients diagnosed with AML and coexisting IDH1/2 mutations leading to DNA hypermethylation and epigenetic dysregulation had more successful outcomes when cladribine was applied in the induction protocol. This evidence concerns the gene IDH1 and acute myeloid leukemia.